Combing biophysical and 'omics methods for understanding the basis of blood clotting and haemostasis, and how to modify it
Lead Research Organisation:
University of Manchester
Department Name: Chemistry
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Publications
Grobbelaar LM
(2022)
Relative Hypercoagulopathy of the SARS-CoV-2 Beta and Delta Variants when Compared to the Less Severe Omicron Variants Is Related to TEG Parameters, the Extent of Fibrin Amyloid Microclots, and the Severity of Clinical Illness.
in Seminars in thrombosis and hemostasis
Kell DB
(2022)
A central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications.
in The Biochemical journal
Pretorius E
(2022)
Prevalence of symptoms, comorbidities, fibrin amyloid microclots and platelet pathology in individuals with Long COVID/Post-Acute Sequelae of COVID-19 (PASC).
in Cardiovascular diabetology
Page MJ
(2022)
The Role of Lipopolysaccharide-Induced Cell Signalling in Chronic Inflammation.
in Chronic stress (Thousand Oaks, Calif.)
Nunes JM
(2022)
The Occurrence of Hyperactivated Platelets and Fibrinaloid Microclots in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).
in Pharmaceuticals (Basel, Switzerland)
Grobbelaar LM
(2021)
SARS-CoV-2 spike protein S1 induces fibrin(ogen) resistant to fibrinolysis: implications for microclot formation in COVID-19.
in Bioscience reports
Pretorius E
(2021)
Persistent clotting protein pathology in Long COVID/Post-Acute Sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin.
in Cardiovascular diabetology
Description | Discovery of amyloid formation by clotting blood. Absolutely humungous discovery. Novel methods for analysing blood in control and unhealthy individuals. In particular, we discovered that blood clots into an unusual form, known as an amyloid form, and this has huge implications. |
Exploitation Route | Novel diagnostics. |
Sectors | Digital/Communication/Information Technologies (including Software) Education Healthcare Pharmaceuticals and Medical Biotechnology |
Description | Stellenbosch |
Organisation | University of Stellenbosch |
Country | South Africa |
Sector | Academic/University |
PI Contribution | Prof Douglas Kell appointed Extraordinary (Honorary) Professor, Department of Physiological Science, Stellenbosch University. Collaborative research in the areas of anti-microbial resistance, membrane transporters, dormant microbes as elements of supposedly non-communicable diseases, iron dysregulation, and enzyme improvement. |
Collaborator Contribution | Sharing of knowledge and analytical facilities at Stellenbosch and Liverpool. |
Impact | See publications. |
Start Year | 2017 |